Bharat Biotech and the University of Maryland Center for Vaccine Development (CVD) announced that they had received a $4 million Strategic Translation Award from The Wellcome Trust for clinical development of a new vaccine against a lethal infectious disease common in sub-Saharan Africa. The vaccine, whose initial clinical trials will begin in three years, is aimed at preventing the invasive non-typhoidal Salmonella (NTS). NTS have emerged as an important cause of invasive bloodstream infection in sub-Saharan Africa, among young children with malaria and malnutrition, and among adults with HIV, said a statement by Hyderabad-based Bharat Biotech.
Strains of NTS that can cause systemic disease such as meningitis or sepsis are particularly common in sub-Saharan Africa. Approximately 20 to 30 percent of children with infections die. ”The CVD NTS project is a testimony of our belief in collaborative research and our commitment to introduce highly effective and affordable vaccines to solve region- specific neglected diseases in the developing world,” said Krishna Ella, Chairman and Managing Director Bharat Biotech. ”This is a collaboration to bring forth a potentially life-saving vaccine for a very underserved population,” said Professor Myron Levine, Director,CVD.